MX2022002311A - Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de monoacilglicerol lipasa (magl). - Google Patents
Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de monoacilglicerol lipasa (magl).Info
- Publication number
- MX2022002311A MX2022002311A MX2022002311A MX2022002311A MX2022002311A MX 2022002311 A MX2022002311 A MX 2022002311A MX 2022002311 A MX2022002311 A MX 2022002311A MX 2022002311 A MX2022002311 A MX 2022002311A MX 2022002311 A MX2022002311 A MX 2022002311A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- hexapyrido
- oxazin
- magl inhibitors
- magl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invención se refiere a nuevos compuestos heterocíclicos que tienen la Fórmula general (I) (ver Fórmula) en donde A, B, L1, X, m, n, y R1 a R7 son como se describen en la presente, composiciones que incluyen los compuestos, procesos de manufacturación de los compuestos y métodos de uso de los compuestos como inhibidores de monoacilglicerol lipasa (MAGL).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19196879 | 2019-09-12 | ||
PCT/EP2020/075260 WO2021048242A1 (en) | 2019-09-12 | 2020-09-10 | 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022002311A true MX2022002311A (es) | 2022-03-25 |
Family
ID=67953598
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022002311A MX2022002311A (es) | 2019-09-12 | 2020-09-10 | Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de monoacilglicerol lipasa (magl). |
Country Status (17)
Country | Link |
---|---|
US (1) | US11814375B2 (es) |
EP (1) | EP4028403B1 (es) |
JP (1) | JP2022548028A (es) |
KR (1) | KR20220062515A (es) |
CN (1) | CN114269755A (es) |
AR (1) | AR119943A1 (es) |
AU (1) | AU2020346350A1 (es) |
BR (1) | BR112022002375A2 (es) |
CA (1) | CA3151516A1 (es) |
CL (1) | CL2022000556A1 (es) |
CO (1) | CO2022001879A2 (es) |
CR (1) | CR20220104A (es) |
IL (1) | IL289186A (es) |
MX (1) | MX2022002311A (es) |
PE (1) | PE20220565A1 (es) |
TW (1) | TW202128706A (es) |
WO (1) | WO2021048242A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10357493B2 (en) | 2017-03-10 | 2019-07-23 | Selenity Therapeutics (Bermuda), Ltd. | Metalloenzyme inhibitor compounds |
AR114136A1 (es) | 2017-10-10 | 2020-07-29 | Hoffmann La Roche | Compuestos heterocíclicos |
JP7269948B2 (ja) | 2017-11-28 | 2023-05-09 | エフ. ホフマン-ラ ロシュ アーゲー | 新規複素環式化合物 |
WO2019134985A1 (en) | 2018-01-08 | 2019-07-11 | F. Hoffmann-La Roche Ag | Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors |
UA127629C2 (uk) | 2018-08-13 | 2023-11-08 | Ф. Хоффманн-Ля Рош Аг | Нові гетероциклічні сполуки як інгібітори моноацилгліцеролліпази |
JP2022548028A (ja) | 2019-09-12 | 2022-11-16 | エフ.ホフマン-ラ ロシュ アーゲー | Magl阻害剤としての4,4a,5,7,8,8a-ヘキサピリド[4,3-b][1,4]オキサジン-3-オン化合物 |
CR20220325A (es) | 2019-12-20 | 2022-08-19 | Tenaya Therapeutics Inc | Fluoroalquil-oxadiazoles y sus usos |
PE20231372A1 (es) | 2020-09-03 | 2023-09-07 | Hoffmann La Roche | Compuestos heterociclicos |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5214038A (en) | 1991-04-15 | 1993-05-25 | Hoechst-Roussel Pharmaceuticals Inc. | 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof |
US7160888B2 (en) | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
US7579495B2 (en) | 2003-12-19 | 2009-08-25 | Momentive Performance Materials Inc. | Active-releasing cyclic siloxanes |
WO2007002057A1 (en) | 2005-06-20 | 2007-01-04 | Schering Corporation | Carbon-linked substituted piperidines and derivatives thereof useful as histamine h3 antagonists |
EP1945222B1 (en) | 2005-11-02 | 2012-12-26 | Bayer Pharma Aktiengesellschaft | Pyrrolo[2,1-f] [1,2,4]-triazin-4-ylamines as igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases |
MX2008010481A (es) | 2006-02-17 | 2008-12-19 | Memory Pharm Corp | Compuestos que tienen afinado para el receptor f-ht6. |
US7872028B2 (en) | 2006-04-05 | 2011-01-18 | Vitae Pharmaceuticals, Inc. | Diaminopropanol renin inhibitors |
TW200942537A (en) | 2008-02-01 | 2009-10-16 | Irm Llc | Compounds and compositions as kinase inhibitors |
JP5552126B2 (ja) | 2008-10-29 | 2014-07-16 | エフ.ホフマン−ラ ロシュ アーゲー | 新規フェニルアミドまたはピリジルアミド誘導体、およびgpbar1アゴニストとしてのそれらの使用 |
WO2011059118A1 (ko) | 2009-11-10 | 2011-05-19 | Kim Hyun Jeen | 후각인지능력 검사 시스템 |
WO2011058766A1 (en) | 2009-11-16 | 2011-05-19 | Raqualia Pharma Inc. | Aryl carboxamide derivatives as ttx-s blockers |
US8420661B2 (en) | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
US9493451B2 (en) | 2011-05-16 | 2016-11-15 | Bionomics Limited | Amine derivatives as potassium channel blockers |
WO2013059118A1 (en) | 2011-10-19 | 2013-04-25 | The Trustees Of Columbia University In The City Of New York | Cyclopropenimine catalyst compositions and processes |
JP2014533747A (ja) | 2011-11-30 | 2014-12-15 | アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd | 3,7−二置換オクタヒドロ−2H−ピリド[4,3−e][1,3]オキサジン−2−オン抗生物質 |
PE20141598A1 (es) | 2011-12-22 | 2014-11-14 | Novartis Ag | Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina |
CN104159581B (zh) | 2012-01-06 | 2017-09-01 | 阿比德治疗公司 | 氨基甲酸酯化合物及其制备和使用方法 |
GB201209587D0 (en) | 2012-05-30 | 2012-07-11 | Takeda Pharmaceutical | Therapeutic compounds |
TW201422625A (zh) | 2012-11-26 | 2014-06-16 | Novartis Ag | 二氫-吡啶并-□衍生物之固體形式 |
US9527867B2 (en) | 2013-04-16 | 2016-12-27 | Actelion Pharmaceuticals Ltd. | Antibacterial biaromatic derivatives |
WO2016109501A1 (en) | 2014-12-30 | 2016-07-07 | Karos Pharmaceuticals, Inc. | Amide compounds as tryptophan hydroxylase inhibitors |
US10106556B2 (en) | 2015-03-30 | 2018-10-23 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
AU2016261031A1 (en) | 2015-05-13 | 2017-10-05 | Selvita S.A. | Substituted quinoxaline derivatives |
CA3199601A1 (en) | 2015-05-21 | 2016-11-24 | Glaxosmithkline Intellectual Property Development Limited | Benzoimidazole derivatives as pad4 inhibitors |
ES2849951T3 (es) | 2015-06-18 | 2021-08-24 | 89Bio Ltd | Derivados de piperidina 4-bencil y 4-benzoil sustituidos |
WO2017087858A1 (en) | 2015-11-20 | 2017-05-26 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
US10323038B2 (en) | 2015-11-20 | 2019-06-18 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
US10610520B2 (en) | 2016-03-31 | 2020-04-07 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
JP6788683B2 (ja) | 2016-03-31 | 2020-11-25 | 武田薬品工業株式会社 | 複素環化合物 |
EA039223B1 (ru) | 2017-06-12 | 2021-12-20 | Бёрингер Ингельхайм Интернациональ Гмбх | Гетероароматические соединения в качестве ингибиторов ванина |
JP7189143B2 (ja) | 2017-09-29 | 2022-12-13 | 武田薬品工業株式会社 | 複素環化合物 |
AR114136A1 (es) | 2017-10-10 | 2020-07-29 | Hoffmann La Roche | Compuestos heterocíclicos |
JP7269948B2 (ja) * | 2017-11-28 | 2023-05-09 | エフ. ホフマン-ラ ロシュ アーゲー | 新規複素環式化合物 |
TW201930300A (zh) | 2017-12-15 | 2019-08-01 | 瑞士商赫孚孟拉羅股份公司 | 新雜環化合物 |
WO2019134985A1 (en) | 2018-01-08 | 2019-07-11 | F. Hoffmann-La Roche Ag | Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors |
BR112020014992A2 (pt) * | 2018-03-22 | 2020-12-29 | F. Hoffmann-La Roche Ag | Inibidores de oxazina monoacilglicerol lipase (magl) |
UA127629C2 (uk) | 2018-08-13 | 2023-11-08 | Ф. Хоффманн-Ля Рош Аг | Нові гетероциклічні сполуки як інгібітори моноацилгліцеролліпази |
KR20210044217A (ko) | 2018-08-13 | 2021-04-22 | 에프. 호프만-라 로슈 아게 | 모노아실글리세롤 리파제 저해제로서의 신규 헤테로시클릭 화합물 |
EP3883928A4 (en) | 2018-11-22 | 2022-06-29 | Qilu Regor Therapeutics Inc. | Glp-1r agonists and uses thereof |
BR112021009348A2 (pt) * | 2018-11-22 | 2021-08-10 | F. Hoffmann-La Roche Ag | compostos heterocíclicos |
WO2020207941A1 (en) | 2019-04-09 | 2020-10-15 | F. Hoffmann-La Roche Ag | Heterocyclic compounds as inhibitors of monoacylglycerol lipase (magl) |
BR112021026820A2 (pt) | 2019-07-03 | 2022-02-22 | Hoffmann La Roche | Inibidores heterocíclicos de monoacilglicerol lipase (magl) |
KR20220034104A (ko) | 2019-07-09 | 2022-03-17 | 에프. 호프만-라 로슈 아게 | 신규 헤테로고리 화합물 |
US20210094971A1 (en) | 2019-09-09 | 2021-04-01 | Hoffmann-La Roche Inc. | Heterocyclic compounds |
JP2022548028A (ja) | 2019-09-12 | 2022-11-16 | エフ.ホフマン-ラ ロシュ アーゲー | Magl阻害剤としての4,4a,5,7,8,8a-ヘキサピリド[4,3-b][1,4]オキサジン-3-オン化合物 |
EP4028402A1 (en) | 2019-09-12 | 2022-07-20 | F. Hoffmann-La Roche AG | Radiolabeled compounds |
CA3155161A1 (en) | 2019-09-23 | 2021-04-01 | F. Hoffmann-La Roche Ag | Heterocyclic compounds |
EP4034541A1 (en) | 2019-09-24 | 2022-08-03 | F. Hoffmann-La Roche AG | Heterocyclic compounds |
WO2021058443A1 (en) | 2019-09-24 | 2021-04-01 | F. Hoffmann-La Roche Ag | Fluorescent probes for monoacylglycerol lipase (magl) |
CN114401968A (zh) | 2019-09-24 | 2022-04-26 | 豪夫迈·罗氏有限公司 | 新颖杂环单酰基甘油脂肪酶(magl)抑制剂 |
PE20231372A1 (es) | 2020-09-03 | 2023-09-07 | Hoffmann La Roche | Compuestos heterociclicos |
-
2020
- 2020-09-10 JP JP2022516054A patent/JP2022548028A/ja active Pending
- 2020-09-10 AU AU2020346350A patent/AU2020346350A1/en active Pending
- 2020-09-10 MX MX2022002311A patent/MX2022002311A/es unknown
- 2020-09-10 KR KR1020227007925A patent/KR20220062515A/ko unknown
- 2020-09-10 PE PE2022000245A patent/PE20220565A1/es unknown
- 2020-09-10 WO PCT/EP2020/075260 patent/WO2021048242A1/en unknown
- 2020-09-10 CN CN202080059190.8A patent/CN114269755A/zh active Pending
- 2020-09-10 CR CR20220104A patent/CR20220104A/es unknown
- 2020-09-10 CA CA3151516A patent/CA3151516A1/en active Pending
- 2020-09-10 EP EP20774901.1A patent/EP4028403B1/en active Active
- 2020-09-10 US US17/017,200 patent/US11814375B2/en active Active
- 2020-09-10 BR BR112022002375A patent/BR112022002375A2/pt unknown
- 2020-09-11 AR ARP200102527A patent/AR119943A1/es unknown
- 2020-09-11 TW TW109131236A patent/TW202128706A/zh unknown
-
2021
- 2021-12-20 IL IL289186A patent/IL289186A/en unknown
-
2022
- 2022-02-22 CO CONC2022/0001879A patent/CO2022001879A2/es unknown
- 2022-03-07 CL CL2022000556A patent/CL2022000556A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
BR112022002375A2 (pt) | 2022-07-19 |
CA3151516A1 (en) | 2021-03-18 |
CR20220104A (es) | 2022-04-20 |
TW202128706A (zh) | 2021-08-01 |
PE20220565A1 (es) | 2022-04-13 |
AR119943A1 (es) | 2022-01-19 |
US20210094943A1 (en) | 2021-04-01 |
WO2021048242A1 (en) | 2021-03-18 |
EP4028403A1 (en) | 2022-07-20 |
IL289186A (en) | 2022-02-01 |
CO2022001879A2 (es) | 2022-03-29 |
CL2022000556A1 (es) | 2022-10-21 |
US11814375B2 (en) | 2023-11-14 |
KR20220062515A (ko) | 2022-05-17 |
JP2022548028A (ja) | 2022-11-16 |
AU2020346350A1 (en) | 2022-02-17 |
EP4028403B1 (en) | 2023-11-22 |
CN114269755A (zh) | 2022-04-01 |
EP4028403C0 (en) | 2023-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022002311A (es) | Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de monoacilglicerol lipasa (magl). | |
MX2020008894A (es) | Inhibidores de oxazin monoacilglicerol lipasa (magl). | |
CR20210077A (es) | Nuevos compuestos heterocíclicos como inhibidores de la monoacilglicerol lipasa | |
CR20210056A (es) | Nuevos compuestos heterocíclicos como inhibidores de monoacilglicerol lipasa | |
MX2022002554A (es) | Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de monoacilglicerol lipasa (magl). | |
CR20220118A (es) | Nuevos inhibidores heterocíclicos de monoacilglicerol lipasa (magl) | |
PH12021551167A1 (en) | New heterocyclic compounds | |
MX2013006101A (es) | Compuestos heterociclicos nitrogenados sustituidos fusionados en posicion 6,6 y usos de los mismos. | |
CR20220116A (es) | Compuestos heterocíclicos | |
CR20220117A (es) | Compuestos heterocíclicos | |
MX2023002224A (es) | Compuestos heterociclicos. | |
MX2022000243A (es) | Nuevos compuestos heterociclicos. | |
CR20230496A (es) | Compuestos heterocíclicos | |
KR20180084423A (ko) | 디아릴플루오렌 아민 유도체 유기화합물 및 이를 포함하는 유기 전계 발광 소자 | |
MX2022005024A (es) | Profarmacos de fosforo de estimuladores de guanilato ciclasa soluble (sgc). | |
BR112013028368A2 (pt) | novos compostos de hexahidrociclopentapirrolona, hexahidropirrolopirrolona, octahidropirrolopiridinona e octahidropiridinona | |
BR112013028945A2 (pt) | novos compostos de hexahidropirroloimidazolona | |
PH12021550320A1 (en) | Bicyclic heteroaryl derivatives | |
GB201013509D0 (en) | Compounds |